Purpose of Review Summarize features of the currently recognized congenital myasthenic syndromes (CMS) with emphasis on novel findings identified in the past 6 years. Recent Findings Since the last review of the CMS in this journal in 2012, several novel CMS were identified. The identified disease proteins are SNAP25B, synaptotagmin 2, Munc13-1, synaptobrevin-1, GFPT1, DPAGT1, ALG2, ALG14, Agrin, GMPPB, LRP4, myosin 9A, collagen 13A1, the mitochondrial citrate carrier, PREPL, LAMA5, the vesicular ACh transporter, and the high-affinity presynaptic choline transporter. Summary Exome sequencing has provided a powerful tool for identifying novel CMS. Identifying the disease genes is essential for determining optimal therapy. The landscape of the CMS is still unfolding.
Introduction
Currently, no fewer than 30 distinct congenital myasthenic syndromes (CMS) are recognized ( Fig. 1) . When the CMS were reviewed in this journal in 2012, only 13 CMS were recognized. The increased number of recognized CMS is likely due to increased awareness of CMS by clinicians and the increased use of next-generation sequencing methods to detect the disease genes and their mutations.
This review considers the salient features, diagnosis, and therapy of the presently identified CMS with emphasis on the more recently identified disorders.
Classification of the Congenital Myasthenic Syndromes
This review classifies the CMS according to the anatomic site of the disease protein (e.g., presynaptic, synaptic space, and postsynaptic), as arising from defects in endplate (EP) development and maintenance, as CMS arising from defects in protein glycosylation, and as miscellaneous other CMS (see Table 1 below). Table 1 indicates that the disease protein located in the presynaptic region in 5.6%, in the synaptic space in 12.9%, in the postsynaptic region in 51.4%, and in both pre-and postsynaptic regions in 12.5%. Moreover, all purely postsynaptic CMS, except those due to a defect in plectin [1] or in the postsynaptic voltage gated Na channel [2] , are caused by mutations in AChR. Of note, mutations in AChR, Rapsyn, AChE, and Dok-7 account for 87% of the 359 CMS patients investigated at the Mayo Clinic.
whole exome sequencing. The identified disease proteins include SNAP25B [3] , synaptotagmin 2 [4] , Munc13-1 [5••] , synaptobrevin-1 [6••, 7 ••], GFPT1 [8, 9] , DPAGT1 [10] , Agrin [11] [12] [13] , ALG2, ALG14 [14] , GMPPB [15] , LRP4 [16••] , myosin 9A [17•] , collagen 13A1 [18••] , the mitochondrial citrate carrier [19] , PREPL [20] , LAMA5 [21] , the vesicular ACh transporter [22••] , and the high-affinity presynaptic choline transporter [23••] .
The Currently Recognized CMS

Paucity of Synaptic Vesicles and Reduced Quantal Release
In this rare CMS, the safety margin of neuromuscular transmission is compromised by the paucity of synaptic vesicles in the nerve terminal which correlates with a decreased store of transmitter quanta available for release and with decreased density of synaptic vesicles in the nerve terminals [24] . The disease gene remains unidentified.
Synaptobrevin-1 Myasthenia
Synaptobrevin-1 is one of the SNARE proteins essential for synaptic vesicle exocytosis. Expression of the A and D isoforms of the gene is predicted at the motor EP. A homozygous mutation in synaptobrevin-1 was detected in a girl hypotonic and weak since infancy who died at age 14 of respiratory failure. Repetitive stimulation studies indicated marked facilitation of the evoked muscle action potential at high frequencies of stimulation. The identified mutation extends the C terminus of both A and D isoforms and exocytosis is hindered by the increased free energy required for fusing the synaptic vesicle with the presynaptic membrane [6••] . Another patient with similar findings was also reported [7••] .
Munc13-1 Myasthenia
This CMS was identified in a paralyzed microcephalic infant with cortical hyperexcitability who carried a homozygous stop codon mutation in MUNC13-1. Munc13-1 is targeted to active zones at all cholinergic neuromuscular synapses and to nearly all glutamatergic synapses in the brain and is required at both sites for docking and priming the synaptic vesicles prior to release. In the inactive state, Munc18 locks syntaxin, another SNARE protein, in a folded state. Upon Ca 2+ entry into the nerve terminal, Munc13 unlocks Syntaxin by displacing Munc18 allowing Syntaxin to interact with Synaptobrevin and SNAP25B to effect vesicle exocytosis. Absence of functioning Munc13-1 relegates syntaxin to a permanently locked state; this inhibits exocytosis, predisposes to seizures, and causes microcephaly by abrogating a role of syntaxin in developing mature neurons [5••] .
Endplate Choline Acetyltransferase Deficiency
This disease causes sudden episodes of apnea against a background of variable myasthenic symptoms [25] . The symptoms respond to pyridostigmine but the most severely ill patients remain respirator dependent and unable to move since birth. Repeated episodes of apnea resulted in cerebral atrophy in some patients [26] . The identified mutations can alter the level of expression, kinetic properties, or structural stability of choline acetyltransferase (ChAT). The most severe kinetic mutations are near the substrate binding site or active site of the enzyme. The mutations are deleterious because they diminish the ACh 
Defects in the Vesicular ACh Transporter and in the High-Affinity Presynaptic Choline Transporter
These defects hinder ACh resynthesis [22••] . Clinical features of generalized myasthenia are associated with sudden episodes of apnea as in patients with ChAT deficiency [22••] .
Synaptotagmin 2 Myasthenia
Synaptotagmin 2 is a presynaptic calcium sensor for exocytosis. Defects in synaptotagmin 2 caused lower limb predominant weakness, areflexia, and low amplitude compound muscle action potentials that were greatly facilitated by exercise as in the Lambert-Eaton syndrome, as well as a motor neuronopathy [4] . The electrophysiology studies are consistent with a presynaptic disorder [27] .
Endplate Acetylcholinesterase Deficiency
The endplate species of acetylcholinesterase (AChE) is composed of catalytic subunits encoded by AChE T and a structural subunit encoded by COLQ. No spontaneous mutations have been observed in AChE T . ColQ, composed of three identical strands, anchors the complex in the synaptic basal lamina, and N terminal residues of each strand bind a catalytic homotetramer. Mutations in the N terminal region of ColQ • Stimulation at 10 Hz for 5 min causes marked decrease of CMAP followed by slow recovery over 10 min. A rapid recovery in 2 to 3 min is not diagnostic • EMG decrement at 2 Hz can be absent at rest but appears after exercise after stimulation at 10 Hz for 5 min, then disappears slowly over 10 min. A rapid recovery in 2 to 3 min is not specific Rapsyn deficiency
• Multiple congenital joint contractures or dysmorphic features in one fourth of patients • Increased weakness and respiratory insufficiency precipitated by intercurrent infections • EMG decrement can be mild or absent Agrin deficiency
• Selective wasting first of distal leg and then of distal arm muscles in some patients • May respond to albuterol; uncertain benefit by pyridostigmine Dok-7 myasthenia
• Proximal greater than distal limb and axial muscle weakness, mild facial weakness and ptosis, normal ocular ductions in the majority • Significant bulbar muscle involvement in some patients • Worsened by cholinesterase inhibitors; responds to albuterol GFPT1 myasthenia
• Proximal and sometimes distal muscle weakness. Ptosis and respiratory weakness uncommon • CK elevation in about one fourth • Tubular aggregates in muscle in most patients; autophagic myopathy in some patients • Improved by cholinergic agonists DPAGT1, ALG2, ALG14, and GMPPB myasthenias
• Limb-girdle or diffuse weakness; ocular ductions spared • Can be associated with congenital malformations and cognitive deficits • Abnormal isoelectric focusing pattern of serum transferrin • Tubular aggregates in muscle in most patients; autophagic myopathy in some patients • Improved by cholinergic agonists SNAP25B myasthenia
• Ataxia, intellectual disability, and cortical hyperexcitability Synaptotagmin 2, Munc13-1, synaptobrevin-1 myasthenias
• Low amplitude evoked CMAP at rest that markedly facilitates on high frequency stimulation, as in the Lambert-Eaton syndrome; hyporeflexia; possible motor neuronopathy in synaptotagmin 2 myasthenia Laminin beta2 myasthenia
• Nephrotic syndrome, ocular abnormalities (Pierson syndrome)
• Refractoriness to cholinesterase inhibitors Plectin deficiency myasthenia
• Epidermolysis bullosa simplex PREPL deficiency myasthenia
• Most cases associated with cystinuria and growth hormone deficiency • Responds to pyridostigmine in infancy; may improve spontaneously after age 1 year Mitochondrial citrate carrier deficiency myasthenia
• Variable developmental anomalies of the eye, brain, and heart Centronuclear myopathy-myasthenia
• High proportion of central myofiber nuclei as the predominant pathologic alteration. Only some patients have a defect of neuromuscular transmission.
There are no specific clues to the diagnosis of the fast-channel congenital myasthenic syndrome, primary endplate AChR deficiency, and most cases of rapsyn deficiency. This table is reproduced by permission from the 2018 MedLink Neurology article "Congenital myasthenic syndromes" prevent its association with the catalytic subunits; frameshift or nonsense mutations in collagenic midsection of ColQ result in an insertion incompetent enzyme; and mutations in the globular C-terminal region prevent insertion of ColQ into the synaptic basal lamina [28, 29] . Absence of AChE from the synaptic space prolongs the endplate potential (EPP), and when this outlasts the absolute refractory period of the muscle fiber, it generates a second (or repetitive) muscle action potential. Cholinergic overactivity can injure the postsynaptic region causing degeneration of the junctional folds with loss of AChR. The nerve terminals are abnormally small which reduce the synaptic vesicles available for release which may protect the postsynaptic region from overexposure to ACh. Neuromuscular transmission is compromised by decreased quantal release, degeneration of junctional folds, and desensitization of AChR by overexposure to ACh [26, 30] . For many years, EP AChE deficiency was considered untreatable. This disease can be improved by ephedrine [31, 32] or albuterol [33] at dosages used in clinical practice.
Laminin Beta 2 Myasthenia
Laminin beta 2, encoded by LAMB2, is a component of the basal lamina and is highly expressed in kidney, eye, and the neuromuscular junction where it promotes the pre-and postsynaptic alignment and interactions. Defects in in this gene cause Pierson syndrome with renal and ocular malformations and with muscle weakness [34] . Neuromuscular transmission is compromised by decreased quantal release by nerve impulse and a low MEPP amplitude. The nerve terminals are reduced in size and often encased by Schwann cells, and the junctional folds are simplified.
Laminin Alpha 5 Myasthenia
Laminin alpha 5, encoded by LAMA5, is another component of the synaptic basal lamina required for development and maturation of the postsynaptic region. A single patient with severe weakness since birth carried a homozygous R2659W mutation in LAMA5. The EMG showed low amplitude CMAP that was markedly facilitated by maximal exercise. Electron microscopy revealed small nerve terminals. Expression studies showed decreased cell adhesion and neurite outgrowth [21] .
COL13A1 Myasthenia
COL13A1 encodes the alpha chain of atypical nonfibrillary collagen. It is localized at the motor endplate where it promotes synaptic development and maturation [35] . Col13A1 is concentrated on the junctional folds from where it is secreted into the synaptic space in an autocrine manner to promote adhesion of the presynaptic and postsynaptic regions. Collagen 13A1-/-mice have small nerve terminals distant from often surrounded by Schwann cells. Synaptic transmission is compromised by small synaptic potentials, decreased probability of spontaneous and evoked quantal release, and postsynaptic AChR deficiency. Three patients in two kinships with variable myasthenic symptoms harbored homozygous loss of function mutations in the alpha chain of COL13A1. Expression of one identified mutations in C2C12 cells reduced the size of AChR clusters [18••] .
CMS Caused by Mutations in AChR
Approximately one-half of the currently identified CMS stem form mutations in AChR subunit genes. The mutations reduce the expression or change the kinetic properties of the receptor. The kinetic mutations fall into two distinct groups: dominant gain-of-function mutations that prolong the openings of the AChR channel and cause slow-channel syndromes and recessive loss-of-function mutations that shorten the openings of the AChR channel and cause fast-channel syndromes. Some low expressor mutations also have minor kinetic effects, and some kinetic mutations also reduce AChR expression.
Low Expressor Mutations Most mutations causing decreased surface expression of AChR reside in the ε subunit because expression of the fetal γ-subunit partially compensates for low or no expression of the ε subunit. Patients with low expressor or null mutations in both alleles of non-ε subunits are infrequent, have very severe disease, and often die in early life. Morphologic studies show small endplate regions distributed over an increased span of the muscle fiber with patchy and faint expression of the receptor [36, 37] . Most patients respond favorably but incompletely to anti-AChE medications, which increases the number of AChRs activated by each quantum. The additional use of 3,4-diaminopyridine (3,4-DAP), which increases the number of ACh quanta released by nerve impulse, results in further significant improvement in about one-third of the patients [38] . Albuterol has an additional beneficial effect in patients not responding well to cholinergic agonists [39] .
Slow-Channel Syndromes
Here, dominant gain-of-function mutations residing in different AChR subunits prolong the opening rate and decrease the closing rate of the AChR ion channel or increase AChR affinity for ACh so that it opens repeatedly during a single episode of ACh occupancy generating repetitive muscle action potentials [40, 41] . This, in turn, allows excessive cation and especially Ca 2+ entry into the postsynaptic region that results in degeneration of the junctional folds with loss of AChR. Neuromuscular transmission is compromised by loss of AChR, altered endplate geometry, and a progressive depolarization block at physiologic rates of stimulation due to consecutive EPPs arising in wake of preceding EPPs [42] . This syndrome is worsened by cholinergic agonists but gradually responds to long-lived open-channel blockers of the AChR like fluoxetine or quinidine [43, 44] .
Fast-Channel Syndromes
In this CMS, one mutant allele of an AChR subunit gene causes abnormally brief AChR channel openings by enhancing the channel closing rate or by curtailing the channel opening rate and the second mutant allele of the same subunit reduces or prevents AChR expression [45] . Decrease in AChR affinity for ACh [46] or altered the fidelity of channel openings also can cause briefer than normal channel openings [47] . Endplate structure is unaffected [46, 48] . The safety margin of neuromuscular transmission is compromised by the decreased probability of channel openings and by the accelerated decay of the synaptic response. This syndrome responds to 3,4-DAP in combination with pyridostigmine.
Defects in Endplate Development and Maintenance
Endplate development and maintenance depend on the interaction of multiple proteins. Agrin released from the nerve terminal interacts with LRP4 and MuSK anchored in the postsynaptic membrane and results in MuSK phosphorylation. The phosphorylated juxtamembrane region of MuSK recruits Dok-7 in the postsynaptic membrane which forms a dimer and stabilizes a dimer of MuSK. Subsequent tyrosine phosphorylation of Dok-7 initiates a signaling pathway that results in anchoring of Rapsyn and AChR to the postsynaptic membrane where MuSK is activated [49••] . CMS can result from mutations in Agrin, MuSK, LRP4, Dok-7, and Rapsyn.
CMS Caused by Defects in Agrin
Agrin is secreted into the synaptic basal lamina by the nerve terminal. It phosphorylates and activates MuSK by way of its receptor LRP4 which activates MuSK [50] . One adult patient with asymmetric eyelid ptosis since birth, no oculoparesis, and mild weakness of facial, hipgirdle, and anterior tibial muscles and refractory to pyridostigmine or 3,4-DAP carried a homozygous p.G1709R missense mutation in AGRN. Light microscopy showed newly formed, underdeveloped EPs and electron microscopy revealed major EP disorganization [11] . A severe myasthenic syndrome was caused in a patient heterozygous for p.Q353X, and p.V1727F. The missense mutation, which determined the phenotype, disrupted the endplate architecture and restricted AChR clustering [12] . A third report describes five kinships with preferential limb muscle wasting, sparing of the axial and cranial muscles, slow progression, and response to albuterol or ephedrine but not to pyridostigmine [13] . Structural studies showed signs of EP degeneration and reorganization.
CMS Caused by Defects in MuSK
Pathogenic mutations in MUSK have severe consequences. In the reported patients, the EPs consist of multiple small regions linked by nerve sprouts and reduced AChR expression [51] . In vitro electrophysiology studies showed reduced MEPP and miniature EP current amplitudes, decreased evoked quantal release, and simplified junctional folds [51] [52] [53] .
CMS Caused by Defects in LRP4 LRP4 located on the postsynaptic membrane is a receptor for agrin and activates MuSK and when bound by agrin. A patient born with two missense mutations, Glu1233Lys and p.Arg1277His both of which impaired binding of LRP4 to both agrin and MuSK, had mild oculoparesis and proximal muscle weakness that was worsened by pyridostigmine. Electron microscopy revealed underdeveloped nerve terminals and postsynaptic regions [54] .
CMS Caused by Defects in Dok-7
Dok-7 was identified as a muscle-intrinsic activator of MuSK [60] and its mutations are a common cause of CMS [55, 56] . The weakness has a limb-girdle distribution but mild ptosis and facial weakness can also occur. Severe bulbar symptoms are uncommon, but some infants can present with stridor and vocal cord paralysis. The clinical course can be static or progressive with conspicuous muscle atrophy. Treatment with cholinergic agonists pyridostigmine and 3,4-DAP aggravates the symptoms. Therapy with adrenergic medications, ephedrine [57, 58] or albuterol [33] , is effective.
The synaptic contacts are small and single or multiple. Electron microscopy reveals ongoing destruction of existing EPs and attempts to form new EPs. Therefore, Dok-7 is essential not only for development but also for maintenance of the EPs [56] . Neuromuscular transmission is compromised by variable decreases in quantal release and by a reduced postsynaptic response to ACh [56, 59] .
CMS Caused by Defects in Rapsyn
Rapsyn, in concert with agrin, LRP4, MuSK, and DOK7, concentrates AChR on the crests of the junctional folds. Mutations in rapsyn cause endplate AChR deficiency [58, [60] [61] [62] . Most patients carry a common N88K mutation, but heteroallelic mutations other than N88K can also occur [63] . EP morphology is similar to that in primary AChR deficiency. Long-term follow-up of 25 patients treated with cholinergic therapy showed that 21 became stable or were clinically improved, 2 patients became asymptomatic, 3 had a progressive course, and 1 died in infancy. Therapy with pyridostigmine combined with 3,4-DAP or albuterol has additional beneficial effects [58] .
CMS Caused by Congenital Defects in Protein Glycosylation
Glycosylation of proteins increases the solubility, folding, stability, assembly, and intracellular transport of nascent peptides. O-glycosylation adds sugar residues to Ser and Thr; N-glycosylation adds multiple sugar residues to Asn. Impaired protein glycosylation affects multiple tissues including muscle and the nervous system. The limb-girdle muscles are selectively affected and often display tubular aggregates of the sarcoplasmic reticulum [64] .
GFPT1 Myasthenia
GFPT1 controls glucose entry into the hexosamine pathway, and thus formation of hexosamine products and precursor availability for N-and O-linked glycosylation of proteins. Pathogenic mutation in GFPT1 results in decreased glycosylation and impaired function of multiple endplate-associated proteins [8] and in hypoplastic endplates [9] . One patient with nonexpression of the muscle-specific GFPT1 exon had low quantal release, small MEPPs, a vacuolar myopathy, and severe weakness of all muscles since birth.
DPAGT1 Myasthenia
DPAGT1 catalyzes the first committed step of N-linked protein glycosylation. Pathogenic mutations in DPAGT1 inhibit N-glycosylation of multiple proteins but in few instances only neuromuscular transmission was selectively affected [10] . In three patients, the myasthenia was associated with intellectual disability and variable response to pyridostigmine. Intercostal muscle studies showed fiber type disproportion, small tubular aggregates, and an autophagic vacuolar myopathy [65] . Quantal release, the endplate potentials, and AChR expression were reduced to approximately half-normal. Immunoblots of muscle showed decreased glycosylation of different proteins, including that of STIM1. STIM1 is a sarcoplasmic reticulum (SR)-associated calcium sensor important for controlling the SR calcium content [66] . Because mutations in STIM1 cause a tubular aggregate myopathy [70] , hypoglycosylation of STIM1 is a likely cause of the tubular aggregates in muscle in patients with defects of N-glycosylation.
ALG2 and ALG14 Myasthenias
ALG2 catalyzes the second and third committed steps of Nglycosylation. ALG14 forms a multiglycosyltransferase complex with ALG13 and DPAGT1 and catalyzes the first committed step of N-glycosylation. These defects are predicted to cause endplate AChR deficiency [14] .
GMPPB Myasthenia
This enzyme subserves the O-glycosylation of α-dystroglycan. Defects in the enzyme result in muscular dystrophy with variable structural changes in brain and ocular abnormalities. Seven of 11 patients in 3 of 6 kinships harboring mutations in GMPBB also had myasthenic symptoms involving predominantly the limb-girdle muscles. Muscle biopsies in six patients revealed dystrophic features. Endplate fine structure and parameters of neuromuscular transmission were not examined [15] .
Sodium Channel Myasthenia
The first observed patient had myasthenic symptoms as well as attacks of normokalemic periodic paralysis. SCN4A, the gene encoding Nav1.4, harbored two mutations (S246L in the S4/S5 linker in domain I and V1442E in S4/S5 linker in domain IV). Nav1.4 expression at patient endplates was normal, and the endplates showed no structural abnormality. Expression studies of V1442E in HEK cells revealed enhanced fast inactivation close to the resting potential and of use-dependent inactivation on high frequency stimulation; S246L had only minor kinetic effects. The safety margin in this syndrome is impaired because a large fraction of the Nav1.4 channels is inexcitable in the resting state [2] . A second patient with similar clinical features harbored a homozygous R1457H mutation in the S4 segment of domain IV that causes reduced depolarization and recovery only after extended repolarization of Nav1.4 [67] . A third patient also carried a homozygous R1454W substitution in the S4 segment of domain IV. This mutation enhances fast and slow inactivation of Nav1.4 and delays recovery from the inactive states [68] .
Plectin Deficiency Myasthenia
Plectin is an intermediate filament-associated protein concentrated at sites of mechanical stress. In normal muscle, it is expressed at the surface membrane, the intermyofibrillar membranous network, the nuclear membrane, and the postsynaptic region of the neuromuscular junction. Defects in plectin cause epidermolysis bullosa simplex, muscular dystrophy, and a myasthenic syndrome in some cases. In two patients, plectin was absent from muscle; the myopathy was associated with dislocated muscle fiber organelles, structurally abnormal nuclei, and focal plasma membrane defects resulting in calcium ingress into the muscle fibers. The endplates showed destruction of the junctional folds. Mutation analysis in each patient revealed two recessive nonsense or frameshift mutations in plectin. The mean MEPP amplitude was reduced to approximately 50% of normal [1, 69] .
PREPL Deficiency Myasthenia
This myasthenia is often associated with hypotonia-cystinuria syndrome caused by recessive deletions of contiguous segments of the SLC3A1 and PREPL genes. An infant harboring a paternally inherited nonsense mutation in PREPL and a maternally inherited deletion involving both PREPL and SLC3A1 had myasthenia and growth hormone deficiency but no cystinuria; therefore, the PREPL deficiency determined the phenotype. The patient responded to pyridostigmine before age 1 year and then improved spontaneously. She had large endplates expressing abundant AChR, small MEPPs, and reduced quantal release. PREPL is an effector of the clathrin associated adaptor protein 1 (AP-1) required for normal function of the vesicular ACh transporter. Hence, absence of PREPL is predicted to result in reduced filling of the synaptic vesicles with ACh and result in a low MEPP amplitude. The cause of the reduced quantal release is not fully understood [20] .
Mitochondrial Citrate Carrier (SLC25A1) Myasthenia
This enzyme mediates exchange of mitochondrial citrate/ isocitrate with cytosolic malate. The exported citrate is then converted to acetyl-CoA and oxaloacetate by ATP-citrate lyase. Dysfunction of the enzyme can interfere with brain, eye, and heart development and impairs neuromuscular transmission. One affected patient had obsessive-compulsive traits, hyperreflexia, and calf hypertrophy, and his affected sister was intellectually challenged. A third patient had agenesis of the corpus callosum, optic atrophy, and seizures. Interestingly, in vitro endplate studies in one patient revealed no AChR deficiency. The MEPP amplitude and evoked quantal release were normal. The cause of the neuromuscular transmission defect remains obscure [19] .
MYO9A Myasthenia
Recessive mutations in MYO9A were identified in a German patient harboring R1517H and R2283H and in two Kurdish siblings with a homozygous D1698G mutation. The protein is expressed at the endplate and plays a role in neuronal branching and axon guidance during neuromuscular junction development. The German patient suffered from proximal and distal muscle weakness, ptosis, episodic apnea, and respiratory failure since birth. The Kurdish siblings had similar symptoms as well as difficulty chewing and swallowing, learning difficulties, and respiratory crises [17•] .
Myasthenic Syndromes Associated with Congenital Myopathies
EMG findings consistent with impaired neuromuscular transmission and a beneficial effect of pyridostigmine have been observed in some patients with centronuclear myopathies caused by mutations in amphiphysin (BIN1) [70] , myotubularin (MTM1) [71] , and dynamin 2 (DNM2) [72] , in tropomyosin 3 (TPM3) [73] , in the ryanodine receptor (RYR) [74] , in centronuclear myopathy without known mutation [75] , and in two cousins with a recessive type of desminopathy [76] .
Prenatal Congenital Myasthenic Syndromes with Fetal Akinesia and Deformations
In humans, AChR containing the γ subunit appears on myotubes around the ninth developmental week and is concentrated at developing EPs around the sixteenth week of gestation. After the 31st developmental week, the fetal γ subunit is replaced by the adult ε subunit [77] . Thus, pathogenic mutations or an autoimmune attack on the AChR γ-subunit result in hypomotility in utero. Fetal hypomotility causes intrauterine growth retardation, small muscle bulk, multiple joint contractures, subcutaneous edema, pterygia (webbing of the neck, axilla, elbows, fingers, or popliteal fossa), lung hypoplasia, campodactyly, rocker-bottom feet with prominent heels, characteristic facies with mild ptosis, and a small mouth with downturned corners [78, 79] . The syndrome is often lethal; the nonlethal form is referred to as the Escobar syndrome. Causes of the syndrome include transplacental transfer from mother to fetus of anti-AChR antibodies with a high-titer of anti-γ-subunit specificities [80] . Myasthenic symptoms are absent at birth because by now the normal epsilon subunit is expressed at the endplates. Lethal forms have also been reported due to biallelic null mutations in the AChR α, β, and δ subunits, as well as in rapsyn and DOK7 [81] [82] [83] [84] .
Conclusions
Mutations in an increasing number of genes are known to cause CMS. In the past 6 years, whole exome sequencing has become a powerful tool for identifying CMS disease genes and mutations. In vitro analysis in affected patients of parameters of neuromuscular transmission combined with examination of neuromuscular junction ultrastructure can inform on the physiologic and morphologic consequences of a mutation. In absence of such studies, expression of the observed mutations in suitable in vitro systems remains an important tool for defining the consequences of the identified mutations and for choosing optimal therapy.
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